Eli Lilly and Company has entered into a strategic collaboration with Ailux, a subsidiary of XtalPi, to discover and develop bispecific antibodies. The partnership will leverage Ailux's artificial intelligence platform to engineer novel antibody therapies for various diseases. Under the terms of the agreement, Lilly gains access to Ailux's AI platform for designing therapeutic candidates. The deal includes upfront and near-term payments, with a total potential value of up to $345 million based on the achievement of development, regulatory, and commercial milestones. Lilly also has an option to license the platform for internal use. This move signals Lilly's increasing commitment to incorporating advanced AI technologies into its research and development pipeline to accelerate the creation of innovative biologic treatments. The collaboration builds on a pre-existing partnership between Lilly and Ailux's parent company, XtalPi. No immediate market reaction analysis was available.